TNF inhibitor naive patients (n = 1,468) | TNF inhibitor continuing patients (n = 733) | TNF inhibitor total patients (n = 2,201) | |||||||
---|---|---|---|---|---|---|---|---|---|
Adalimumab (n = 669) | Etanercept (n = 628) | Infliximab (n = 171) | Adalimumab (n = 248) | Etanercept (n = 367) | Infliximab (n = 118) | Adalimumab (n = 917) | Etanercept (n = 995) | Infliximab (n = 289) | |
Mean age1 | 57 | 58 | 58 | 56 | 55 | 55 | 56 | 57 | 56 |
Female2, % | 88 | 88 | 89 | 87 | 89 | 86 | 88 | 89 | 88 |
Charlson Comorbidities Index1,3 | 1.62 | 1.69 | 1.52 | 1.49 | 1.35 | 1.42 | 1.58 | 1.56 | 1.48 |
1. Myocardial infarction | 1.08% | 2.20% | 0.61% | 0.43% | 0.91% | 1.89% | 0.91% | 1.74% | 1.11% |
2. Congestive heart failure | 4.62% | 4.06% | 3.05% | 4.33% | 3.66% | 1.89% | 4.54% | 3.92% | 2.59% |
3. Peripheral vascular disease | 4.00% | 6.60% | 4.88% | 3.90% | 3.96% | 5.66% | 3.97% | 5.66% | 5.19% |
4. Cerebrovascular disease | 4.46% | 3.72% | 2.44% | 1.73% | 2.74% | 1.89% | 3.75% | 3.37% | 2.22% |
5. Dementia | 0.46% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.34% | 0.22% | 0.00% |
6. Chronic pulmonary disease | 14.46% | 14.38% | 9.15% | 19.91% | 14.33% | 11.32% | 15.89% | 14.36% | 10.00% |
7. Peptic ulcer disease | 2.92% | 2.20% | 2.44% | 2.60% | 1.83% | 5.66% | 2.84% | 2.07% | 3.70% |
8. Mild liver disease | 9.54% | 9.64% | 8.54% | 8.66% | 4.88% | 9.43% | 9.31% | 7.94% | 8.89% |
9. Diabetes without chronic complication | 10.15% | 13.54% | 9.15% | 9.96% | 8.54% | 9.43% | 10.10% | 11.75% | 9.26% |
10. Diabetes with chronic complication | 2.31% | 4.91% | 3.05% | 2.16% | 2.13% | 4.72% | 2.27% | 3.92% | 3.70% |
11. Hemiplegia or paraplegia | 0.92% | 0.68% | 0.00% | 0.43% | 0.61% | 0.00% | 0.79% | 0.65% | 0.00% |
12. Renal disease | 3.85% | 4.40% | 5.49% | 1.73% | 4.57% | 0.94% | 3.29% | 4.46% | 3.70% |
13. Any malignancy. including lymphoma and leukaemia. except malignant neoplasm of skin | 2.46% | 4.23% | 3.05% | 1.30% | 1.83% | 2.83% | 2.16% | 3.37% | 2.96% |
14. Moderate or severe liver disease | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | 0.00% | 0.00% | 0.11% | 0.00% |
15. Metastatic solid tumour | 0.31% | 0.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.23% | 0.11% | 0.00% |
16. AIDS/HIV | 0.00% | 0.17% | 0.00% | 0.43% | 0.00% | 0.00% | 0.11% | 0.11% | 0.00% |
F- and p-values | |||||||||
Mean age | Gender | Charlson index | Mean age | Gender | Charlson index | Mean age | Gender | Charlson index | |
Adalimumab vs. etanercept | 2.6254 | 1.000 | 1.3998 | 1.679 | 0.957 | 2.205 | 0.7768 | 1.000 | 0.5637 |
Adalimumab vs. infliximab | 1.5851 | 1.000 | 1.3518 | 1.455 | 1.000 | 0.803 | 0.1062 | 1.000 | 2.0666 |
Etanercept vs. infliximab | 0.1165 | 1.000 | 2.2446 | 0.233 | 0.825 | 0.8645 | 0.4249 | 1.000 | 1.7001 |
Tukey-Kramer | Bonferroni | Tukey-Kramer | Tukey-Kramer | Bonferroni | Tukey-Kramer | Tukey-Kramer | Bonferroni | Tukey-Kramer |